Importantly, combining FTO inhibitor treatment with existing therapeutic agents, such as standard chemotherapeutic agents or RTK inhibitors, enhances antitumor efficacy in leukemia patients, especially those with high FTO expression and relapsed/refractory AML [53, 74]. The gene discussed is FTO; the disease is leukemia.